In general, the results of the review reveal that LY3437943 has a safety and tolerability profile much like other incretins, with pharmacokinetic and pharmacodynamic outcomes that aid further clinical evaluation. In vivo exploration, in humans, signifies that retatrutide activates and is also a full agonist of all of the incretin receptors which